LPL Financial’s Iterum Therapeutics ITRM Stock Holding History

LPL Financial’s Portfolio ITRM Stock Details ITRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-933	Closed	-$5K	–	4485
2022 Q1	$5K	Hold	933	–	–	﹤0.01%	4168
2021 Q4	$5K	Buy	+933	New	+$7.21K	﹤0.01%	4331

Other funds holding ITRM

CPX

Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return

Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return

LPL Financial's ITRM Position: Q2 2022 in Review

LPL Financial sold out of Iterum Therapeutics (ITRM) in Q2 2022, closing a stake of 933 shares — an estimated $5K sold.

LPL Financial first reported a position in ITRM in Q4 2021 and held it in 2 quarters. The position peaked at $5K in Q1 2022. 38 funds tracked by Wall St. Rank hold ITRM as of Q2 2022.

LPL Financial reported no remaining Iterum Therapeutics position as of Q2 2022 after selling out during the quarter.
LPL Financial sold 933 Iterum Therapeutics shares in Q2 2022, an estimated $5K.
LPL Financial first reported a position in Iterum Therapeutics in Q4 2021 and held it in 2 quarters.
LPL Financial's Iterum Therapeutics position peaked at $5K in Q1 2022.
38 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2022.

Based on LPL Financial's 13F filing for Q2 2022, filed 12 Aug 2022.